Related Experiment Video
Updated: May 17, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Enfuvirtide and cutaneous injection-site reactions
Raul A Mirza1, George W Turiansky
1Preventive Medicine and Occupational & Environmental Medicine Residency Program, Walter Reed Army Medical Center, Washington DC, USA. raulalexandermirza@gmail.com
Abstract:
Enfuvirtide belongs to a newer class of antiretroviral (ARV) agents called fusion inhibitors for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. Enfuvirtide blocks attachment, binding, and entry of the viral capsid into the host CD4+ cell. Administration is only available subcutaneously in a twice-daily regimen particularly for those patients who have previously failed more than one ARV regimen. Common side effects of enfuvirtide administration include fatigue, insomnia, nausea, and diarrhea; however, injection-site reactions are the most common side effect and present in nearly all individuals undergoing treatment. The spectrum of cutaneous manifestations ranges from little to no reaction to cysts, nodules, induration, or sclerodermalike lesions. These reactions are mostly variants of iatrogenically induced hypersensitivity and are self-limited.
Related Concept Videos
Hypersensitivity Reactions: Cytolytic Reactions
Hypersensitivity Reactions: Immune-Complex Reactions
Inhibitors of Viral Protein Synthesis
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions
Subviral Agents
